中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 2
Feb.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(2): 272-277

Clinical management of patients with hepatitis D

DOI: 10.12449/JCH260204
  • 1.

    The Fourth Clinical Medical College of Xinjiang Medical University，Urumqi 830099，China

  • 2.

    Department of Hepatology，Affiliated Traditional Chinese Medical Hospital of Xinjiang Medical University，Urumqi 830099，China

Research funding:

Xinjiang Uygur Autonomous Region “Tianshan Elite” High-level Medical and Health Personnel Training Program (TSYC202401B161)

More Information
  • Corresponding author: WANG Xiaozhong， wxz125@sina.com （ORCID： 0000-0002-9389-9232）
  • Received Date: 2025-12-08
  • Accepted Date: 2026-02-24
  • Published Date: 2026-02-25
    Abstract
  • Hepatitis D virus （HDV）， as a defective virus， relies on the envelope protein of hepatitis B virus （HBV） to complete replication and transmission. Chronic hepatitis B （CHB） patients comorbid with HDV infection may experience significant acceleration of liver disease progression and a significantly higher risk of serious complications such as liver cirrhosis and hepatocellular carcinoma （HCC） compared with the patients with CHB alone， which poses a serious threat to the life and health of patients. At present， the coverage rate of HDV screening needs to be improved， and some patients with HBV/HDV co-infection have not been found in time. Therefore， strengthening the understanding of HDV among clinicians， expanding the scope of HDV screening， identifying patients with infection in a timely manner， and performing standardized antiviral therapy and long-term follow-up management are of great significance for improving the prognosis of patients， reducing disease burden， improving the quality of life of patients， and achieving the global goal of “eliminating viral hepatitis as a public health threat by 2030”.

     

    • FullText(HTML)
  • loading
    • References(43)
  • [1]
    European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis delta virus[J]. J Hepatol, 2023, 79( 2): 433- 460. DOI: 10.1016/j.jhep.2023.05.001.
    [2]
    URBAN S, NEUMANN-HAEFELIN C, LAMPERTICO P. Hepatitis D virus in 2021: Virology, immunology and new treatment approaches for a difficult-to-treat disease[J]. Gut, 2021, 70( 9): 1782- 1794. DOI: 10.1136/gutjnl-2020-323888.
    [3]
    SAGNELLI C, PISATURO M, CURATOLO C, et al. Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic[J]. World J Gastroenterol, 2021, 27( 42): 7271- 7284. DOI: 10.3748/wjg.v27.i42.7271.
    [4]
    YU Z, YANG YP. Concurrent hepatitis D virus infection increases risk of hepatocellular carcinoma in patients with chronic hepatitis B[J]. J Clin Hepatol, 2020, 36( 4): 944- 947.

    于哲, 杨永平. HDV重叠感染可增加慢性乙型肝炎患者的肝细胞癌风险[J]. 临床肝胆病杂志, 2020, 36( 4): 944- 947.
    [5]
    World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection[R]. Geneva: World Health Organization, 2024.
    [6]
    CORNBERG M, SANDMANN L, JAROSZEWICZ J, et al. EASL clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2025, 83( 2): 502- 583. DOI: 10.1016/j.jhep.2025.03.018.
    [7]
    Clinical Practice Guidelines Committee Chair, Osiowy C, Members Panel, et al. The management of chronic hepatitis B: 2025 guidelines update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada[J]. Can Liver J, 2025, 8( 2): 368- 440. DOI: 10.3138/canlivj-2025-0012-e.
    [8]
    TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67( 4): 1560- 1599. DOI: 10.1002/hep.29800.
    [9]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B[J]. Infect Dis Inf, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
    [10]
    BOUZIDI K EL, ELAMIN W, KRANZER K, et al. Hepatitis delta virus testing, epidemiology and management: A multicentre cross-sectional study of patients in London[J]. J Clin Virol, 2015, 66: 33- 37. DOI: 10.1016/j.jcv.2015.02.011.
    [11]
    LIU HM, TAN ZX, YANG J, et al. Prevalence and clinical characteristics of hepatitis D in Southwest of China[J]. Chin J Exp Clin Virol, 2022, 36( 1): 85- 91. DOI: 10.3760/cma.j.cn112866-20210611-00096.

    刘慧敏, 谭朝霞, 杨京, 等. 中国西南地区丁型肝炎的流行状况与临床特征分析[J]. 中华实验和临床病毒学杂志, 2022, 36( 1): 85- 91. DOI: 10.3760/cma.j.cn112866-20210611-00096.
    [12]
    PALOM A, RANDO-SEGURA A, VICO J, et al. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D[J]. JHEP Rep, 2022, 4( 10): 100547. DOI: 10.1016/j.jhepr.2022.100547.
    [13]
    BUTI M, DOMÍNGUEZ-HERNÁNDEZ R, PALOM A, et al. Impact of hepatitis D reflex testing on the future disease burden: A modelling analysis[J]. Liver Int, 2023, 43( 12): 2611- 2614. DOI: 10.1111/liv.15776. DOI: 10.1111/liv.15776.
    [14]
    WINER BY, GASKA JM, LIPKOWITZ G, et al. Analysis of host responses to hepatitis B and delta viral infections in a micro-scalable hepatic co-culture system[J]. Hepatology, 2020, 71( 1): 14- 30. DOI: 10.1002/hep.30815.
    [15]
    NEGRO F, LOK AS. Hepatitis D: A Review[J]. JAMA, 2023, 330( 24): 2376- 2387. doi: 10.1001/jama.2023.23242.
    [16]
    SAGNELLI C, SAGNELLI E, RUSSO A, et al. HBV/HDV co-infection: epidemiological and clinical changes, recent knowledge and future challenges[J]. Life(Basel), 2021, 11( 2): 169. DOI: 10.3390/life11020169.
    [17]
    RAMACHANDRAN K, AGARWAL R, SHARMA MK, et al. Prevalence of hepatitis delta virus infection among hepatitis B virus-infected and exposed patients[J]. J Glob Infect Dis, 2020, 12( 4): 197- 201. DOI: 10.4103/jgid.jgid_137_19.
    [18]
    GISH RG, WONG RJ, di TANNA GL, et al. Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis[J]. Hepatology, 2024, 79( 5): 1129- 1140. DOI: 10.1097/HEP.0000000000000642.
    [19]
    WANG ZG, WU X, DOU J, et al. Analysis of the prevalence status and clinical characteristics of the hepatitis D virus in the Xinjiang region[J]. Chin J Hepatol, 2025, 33( 11): 1058- 1063. DOI: 10.3760/cma.j.cn501113-20250110-00018

    王转国, 吴旭, 窦婧, 等. 新疆地区丁型肝炎病毒的流行状况与临床特征分析[J]. 中华肝脏病杂志, 2025, 33( 11): 1058- 1063. DOI: 10.3760/cma.j.cn501113-20250110-00018.
    [20]
    BÉGUELIN C, MORADPOUR D, SAHLI R, et al. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients[J]. J Hepatol, 2017, 66( 2): 297- 303. DOI: 10.1016/j.jhep.2016.10.007.
    [21]
    ZHENG RJ, LU XB. Epidemiological situation of hepatitis D in Xinjiang, China[J]. J Clin Hepatol, 2023, 39( 4): 766- 770. DOI: 10.3969/j.issn.1001-5256.2023.04.005.

    郑嵘炅, 鲁晓擘. 新疆地区丁型肝炎的流行概况[J]. 临床肝胆病杂志, 2023, 39( 4): 766- 770. DOI: 10.3969/j.issn.1001-5256.2023.04.005.
    [22]
    ASSELAH T, CHATTERGOON MA, JUCOV A, et al. A phase 2 trial of tobevibart plus elebsiran in hepatitis D[J]. N Engl J Med, 2026, 394( 4): 343- 353. DOI: 10.1056/nejmoa2508827.
    [23]
    PAPATHEODORIDI M, SEVASTIANOS V, ZACHOU K, et al. HERACLIS_BLV_D: Increasing response rates during 2-year bulevirtide real-life therapy in chronic hepatitis D[J]. Liver Int, 2025, 45( 7): e70151. DOI: 10.1111/liv.70151.
    [24]
    WEDEMEYER H, ALEMAN S, BRUNETTO M, et al. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial[J]. J Hepatol, 2024, 81( 4): 621- 629. DOI: 10.1016/j.jhep.2024.05.001.
    [25]
    LAMPERTICO P, ALEMAN S, BRUNETTO M, et al. P135 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301[J]. Gut, 2024, 73( Suppl 3): A96- A97. DOI: 10.1136/gutjnl-2024-BASL.137.
    [26]
    HAMID SS, XIE Y, ABBAS Z, et al. Efficacy and safety of libevitug(HH-003) in patients with chronic hepatitis D virus infection from an international, multicenter, randomized, controlled, open-label phase 2b study[abstract][C]. Hepatology, 2025, 72( Suppl 1): 5007.
    [27]
    WEDEMEYER H, YURDAYDIN C, DALEKOS G N, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta[J]. N Engl J Med, 2011, 364( 4): 322- 331. DOI: 10.1056/NEJMoa0912696.
    [28]
    HEIDRICH B, YURDAYDIN C, KABACAM G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta[J]. Hepatology, 2014, 60( 1): 87- 97. DOI: 10.1002/hep.27102.
    [29]
    LAMPERTICO P, BOGOMOLOV PO, CHULANOV V, et al. Phase 2 randomised study of bulevirtide as monotherapy or combined with Peg-IFNα-2a as treatment for chronic hepatitis delta[J]. Liver Int. 2025, 45( 2): e70008. DOI: 10.1111/liv.70008.
    [30]
    LAU DT, DOO E, PARK Y, et al. Lamivudine for chronic delta hepatitis[J]. Hepatology, 1999, 30( 2): 546- 549. DOI: 10.1002/hep.510300217.
    [31]
    PALOM A, SOPENA S, RIVEIRO-BARCIELA M, et al. One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease[J]. Aliment Pharmacol Ther, 2021, 54( 4): 462- 469. DOI: 10.1111/apt.16485.
    [32]
    YURDAYDIN C, KESKIN O, YURDCU E, et al. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis[J]. Hepatology, 2022, 75( 6): 1551- 1565. DOI: 10.1002/hep.32259.
    [33]
    BAZINET M, PÂNTEA V, PLACINTA G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection Naïve to nucleos(t)ide therapy[J]. Gastroenterology, 2020, 158( 8): 2180- 2194. DOI: 10.1053/j.gastro.2020.02.058.
    [34]
    ETZION O, HAMID S, LURIE Y, et al. Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial[J]. Hepatology, 2023, 77( 6): 2093- 2103. DOI: 10.1097/HEP.0000000000000309.
    [35]
    YURDAYDIN C, ABBAS Z, BUTI M, et al. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy[J]. J Hepatol, 2019, 70( 5): 1008- 1015. DOI: 10.1016/j.jhep.2018.12.022.
    [36]
    HERMANUSSEN L, LAMPALZER S, BOCKMANN JH, et al. Non-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D[J]. Front Med(Lausanne), 2023, 10: 1169096. DOI: 10.3389/fmed.2023.1169096.
    [37]
    DOU J, ZHAO XY, WANG ZG, et al. Hepatitis B virus and hepatitis D virus co-infection complicated by autoimmune hepatitis: Two case reports[J]. World J Clin Cases, 2025, 13( 26): 104421. DOI: 10.12998/wjcc.v13.i26.104421.
    [38]
    LIANG HQ, ZHENG XT, LIU YY, et al. Effects of different antiviral treatments on liver inflammation and fibrosis in patients with chronic hepatitis B[J]. J Viral Hepat, 2025, 32( 4): e70019. DOI: 10.1111/jvh.70019.
    [39]
    ROULOT D, BRICHLER S, LAYESE R, et al. High diagnostic value of transient elastography for advanced fibrosis and cirrhosis in patients with chronic hepatitis delta[J]. Clin Gastroenterol Hepatol, 2025, 23( 6): 978- 986.e4. DOI: 10.1016/j.cgh.2024.08.008.
    [40]
    JOHN BV, BASTAICH D, AMOLI MM, et al. Association of HDV infection and HCC, hepatic decompensation, and all-cause and liver-related death in a national cohort[J]. Hepatology, 2025, 81( 6): 1822- 1835. DOI: 10.1097/HEP.0000000000001092.
    [41]
    MIAO ZJ, ZHANG SS, OU XM, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection[J]. J Infect Dis, 2020, 221( 10): 1677- 1687. DOI: 10.1093/infdis/jiz633.
    [42]
    ROULOT D, LAYESE R, BRICHLER S, et al. Hepatitis D virus infection markedly increases the risk of hepatocellular carcinoma in patients with viral B cirrhosis[J]. Clin Gastroenterol Hepatol, 2025, 23( 11): 1943- 1953. e 2. DOI: 10.1016/j.cgh.2024.08.046.
    [43]
    TZARTZEVA K, OBI J, RICH NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis[J]. Gastroenterology, 2018, 154( 6): 1706- 1718. e 1. DOI: 10.1053/j.gastro.2018.01.064.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (32) PDF downloads(31) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return